![Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial - The Lancet Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial - The Lancet](https://www.thelancet.com/cms/asset/4b0be126-d77f-42f1-a9c2-5fa0b3518849/gr1.jpg)
Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial - The Lancet
![Heart Failure Hub Scotland: transforming care for people living with the syndrome - The Heart Failure Policy Network | The Heart Failure Policy Network Heart Failure Hub Scotland: transforming care for people living with the syndrome - The Heart Failure Policy Network | The Heart Failure Policy Network](https://www.hfpolicynetwork.org/wp-content/themes/hfpn-theme/images/torch.png)
Heart Failure Hub Scotland: transforming care for people living with the syndrome - The Heart Failure Policy Network | The Heart Failure Policy Network
![Heart Failure Hub Scotland: transforming care for people living with the syndrome - The Heart Failure Policy Network | The Heart Failure Policy Network Heart Failure Hub Scotland: transforming care for people living with the syndrome - The Heart Failure Policy Network | The Heart Failure Policy Network](https://www.hfpolicynetwork.org/wp-content/uploads/Scottish-parliament_licensed-scaled.jpeg)